Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder

Bibliography

• Baron-Cohen S, Scott FJ, Allison C, et al. Prevalence of autism-spectrum conditions: UK school based population study. Br J Psychiatry 2009;194:500-9
   PubMed Web of Science ®Google Scholar
• Brugha TS, McManus S, Bankart J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 2011;68(5):459-65
   PubMed Web of Science ®Google Scholar
• Autism and Developmental Disabilities Monitoring Network. Prevalence of Autism Spectrum Disorder among children aged 8 years. MMWR Surveill Summ 2014;63(2):1-21
   Web of Science ®Google Scholar
• Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011;168(9):904-12
   PubMed Web of Science ®Google Scholar
• Charman T, Pickles A, Simonoff E, et al. IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP). Psychol Med 2011;41(3):619-27
   PubMed Web of Science ®Google Scholar
• Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil 2007;28(4):341-52
   PubMed Web of Science ®Google Scholar
• NICE: National Institute for Health and Care Excellence. Autism: The management and support of children and young people on the autism spectrum. Clinical Guideline 170. National Health Service, National Collaborating Centre for Mental Health; London, UK: 2013
   Google Scholar
• Volkmar F, Siegel M, Woodbury-Smith M, et al. Treatment of children and adolescents with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2014;53(2):237-57
   PubMed Web of Science ®Google Scholar
• Brentani H, Silvestre de Paula C, Bordini D, et al. Autism spectrum disorders: an overview of diagnosis and treatment. Rev Bras Psiquiatr 2013;25:s62-72
   Google Scholar
• Orinstein AJ, Helt M, Troyb E, et al. Intervention for optimal outcome in children and adolescents with a history of autism. J Dev Behav Pediatr 2014;35:247-56
   PubMed Web of Science ®Google Scholar
• Howard JS, Stanislaw H, Green G, et al. Comparison of behavior analytic and eclectic early interventions for young children with autism after three years. Res Dev Disabil 2014;35(12):3326-44
   PubMed Web of Science ®Google Scholar
• Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: a review. J Appl Behav Anal 2003;36(2):147-85
   PubMed Web of Science ®Google Scholar
• Coury DL, Anagnostou E, Manning-Courtney P, et al. Use of psychotropic medication in children and adolescens with autism spectrum disorders. Pediatrics 2012;130:s69-76
   PubMed Web of Science ®Google Scholar
• Hsia Y, Wong AYS, Murphy DGM, et al. Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology (Berl) 2014;231:999-1009
   PubMed Web of Science ®Google Scholar
• Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007;24(1):CD005040
   Google Scholar
• West L, Waldrop J. Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nurs 2006;32(6):545-9
   PubMedGoogle Scholar
• Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9(5):343-54
   PubMedGoogle Scholar
• Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 2012;26(4):291-9
   PubMed Web of Science ®Google Scholar
• Wong AY, Hsia Y, Chan EW, et al. The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries. Autism Res 2014;7(5):543-54
   PubMed Web of Science ®Google Scholar
• Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in Autism Spectrum Disorder. Harv Rev Psychiatry 2014;22(2):76-92
   PubMed Web of Science ®Google Scholar
• Canitano R. New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr 2014;2:61-6
   PubMed Web of Science ®Google Scholar
• Kanne SM, Mazurek MO. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord 2001;41:926-37
   Google Scholar
• Lecavalier L, Leone S, Wiltz J. Impact of behavior problems on caregiver stress in young people with autism spectrum disorders. J Intellect Disabil Res 2006;50(3):172-83
   PubMed Web of Science ®Google Scholar
• Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov 2003;2:315-20
   PubMed Web of Science ®Google Scholar
• Matone M, Localio R, Huang YS, et al. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of US. Medicaid-enrolled children. Health Serv Res 2012;47(5):1836-60
   PubMed Web of Science ®Google Scholar
• Janssen-Cilag Ltd. Risperdal tablets, liquid & quicklet. summary of product characteristics. Buckinhamshire, 2013. Available from: www.medicines.org.uk/emc/medicine/12818/SPC/ [Last accessed 23 May 2014]
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. Risperdal (risperidone) Prescribing Information. Titusville, 2009. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf [Last accessed 21 July 2014]
   Google Scholar
• Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1998;247:661-70
   Google Scholar
• Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Disp 1993;21:1134-41
   PubMed Web of Science ®Google Scholar
• De Meulder MD, Remmerie BMM, de Vries R, et al. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. J Chromatogr B 2008;870:8-16
   PubMed Web of Science ®Google Scholar
• Casaer P, Walleghem D, Vandenbussche I, et al. Pharmacokinetics, safety of risperidone in autistic children. Pediatr Neurol 1994;11:89
   Google Scholar
• McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 1997;36(5):685-93
   PubMed Web of Science ®Google Scholar
• Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997;33(1):155-9
   PubMed Web of Science ®Google Scholar
• Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37(4):372-6
   PubMed Web of Science ®Google Scholar
• Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10(2):79-90
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40(10):1206-14
   PubMed Web of Science ®Google Scholar
• Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002;41(2):140-7
   PubMed Web of Science ®Google Scholar
• Diler RS, Firat S, Avci A. An open label trial of risperidone in children with autism. Curr Ther Res Clin Exp 2002;63:91-102
   Web of Science ®Google Scholar
• Mukaddes NM, Abali O, Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry 2004;5(4):211-14
   PubMed Web of Science ®Google Scholar
• Gagliano A, Germanò E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004;14(1):39-47
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-41
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347(5):314-21
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology-Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005;162:1361-9
   PubMed Web of Science ®Google Scholar
• Arnold LE, Farmer C, Chmura Kraemer H, et al. Moderators, mediators and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010;20(2):83-93
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114(5):e634-41
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Bossie CA, Youssef E, et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007;37:367-73
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005;162:1142-8
   PubMed Web of Science ®Google Scholar
• Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acas Child Adolesc Psychiatry 2006;45(4):431-9
   PubMed Web of Science ®Google Scholar
• Canitano R. Self injurious behavior in autism: clinical aspects and treatment with risperidone. J Neural Transm 2006;113(3):425-31
   PubMed Web of Science ®Google Scholar
• Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21(6):450-5
   PubMed Web of Science ®Google Scholar
• Rausch JL, Sirota EL, Londino DL, et al. Open-label risperidone for Asperger’s Disorder: negative symptom spectrum response. J Clin Psychiatry 2005;66:1592-7
   PubMed Web of Science ®Google Scholar
• Capone GT, Goyal P, Grados M, et al. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr 2008;29(2):106-16
   PubMed Web of Science ®Google Scholar
• Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16(5):575-87
   PubMed Web of Science ®Google Scholar
• Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001;11(3):229-38
   PubMed Web of Science ®Google Scholar
• Hellings JA, Zarcone JR, Valdovinos MG, et al. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15(6):885-92
   PubMed Web of Science ®Google Scholar
• Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 2006;36(3):401-11
   PubMed Web of Science ®Google Scholar
• Hellings JA, Cardona AM, Schroeder SR. Long-term safety and adverse events of risperidone in children, adolescents, and adults with pervasive developmental disorders. J Ment Health Res Intellect Disabil 2010;3:132-44
   Web of Science ®Google Scholar
• Russo N, Flanagan T, Iarocci G, et al. Deconstructing executive deficits among persons with autism: implications for cognitive neuroscience. Brain Cogn 2007;65(1):77-86
   PubMed Web of Science ®Google Scholar
• Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44(11):1137-44
   PubMed Web of Science ®Google Scholar
• Troost PW, Althaus M, Lahuis BE, et al. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. J Child Adolesc Psychopharmacol 2006;16(5):561-73
   PubMed Web of Science ®Google Scholar
• Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 2008;18(3):227-36
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 2000;68:29-39
   PubMed Web of Science ®Google Scholar
• Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004;161(6):1125-7
   PubMed Web of Science ®Google Scholar
• Lindsay RL, Arnold LE, Aman MG, et al. Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. J Intellect Dev Disabil 2006;31(4):204-9
   PubMed Web of Science ®Google Scholar
• Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50
   PubMed Web of Science ®Google Scholar
• Kent JM, Hough D, Singh J, et al. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2013;23(10):676-86
   PubMed Web of Science ®Google Scholar
• Kent JM, Kushner S, Ning X, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 2013;43:1773-83
   PubMed Web of Science ®Google Scholar
• Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010;10(5):418-30
   PubMed Web of Science ®Google Scholar
• Ecker C, Spooren W, Murphy D. Developing new pharmacotherapies for autism. J Intern Med 2013;274(4):308-20
   PubMed Web of Science ®Google Scholar
• Youngster I, Zachor DA, Gabis LV, et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol 2014;56(10):990-4
   PubMed Web of Science ®Google Scholar
• Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007;27(1):52-7
   PubMed Web of Science ®Google Scholar
• Nurmi EL, Spilman SL, Whelan F, et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry 2013;3:e274
   PubMed Web of Science ®Google Scholar
• Hoekstra PJ, Troost PW, Lahuis BE, et al. Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol 2010;20(6):473-7
   PubMed Web of Science ®Google Scholar
• Miral S, Gencer O, Neslihan Inal-Emiroglu F, et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008;17:1-8
   PubMed Web of Science ®Google Scholar
• Gencer O, Neslihan Inal-Emiroglu F, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder: an open label maintenance study. Eur Child Adolesc Psychiatry 2008;17:217-25
   PubMed Web of Science ®Google Scholar
• Ishitobi M, Kosaka H, Takahashi T, et al. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study. Clin Neuropharmacol 2013;36(5):151-6
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 2014;45(2):185-92
   PubMed Web of Science ®Google Scholar
• Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009;48(12):1143-54
   PubMed Web of Science ®Google Scholar
• Scahill L, McDougle CJ, Aman MG, et al. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. Am Acad Child Adolesc Psychiatry 2012;51(2):136-46
   PubMed Web of Science ®Google Scholar
• Arnold LW, Aman MG, Li X, et al. Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up. J Am Acad Child Adolesc Psychiatry 2012;51(11):1173-84
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008;39(3):237-45
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(1):32-6
   PubMed Web of Science ®Google Scholar
• Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(7):1269-72
   PubMed Web of Science ®Google Scholar
• Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013;225(1):51-9
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013;16(4):783-9
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Mohammadi E, Mohammadi MR, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs 2013;15(6):505-14
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry 2013;13:196
   PubMed Web of Science ®Google Scholar
• Mohammadi MR, Yadegari N, Hassanzadeh E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin Neuropharmacol 2013;36(6):179-84
   PubMed Web of Science ®Google Scholar
• Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev 2012;43(5):674-82
   PubMed Web of Science ®Google Scholar
• Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 2009;19(2):101-9
   PubMed Web of Science ®Google Scholar
• Curtin C, Anderson SE, Must A, Bandini L. The prevalence of obesity in children with autism: a secondary data analysis using nationally representative data from the National Survey of Children’s Health. BMC Pediatr 2010;10:11
   PubMed Web of Science ®Google Scholar
• Crosland KA, Zarcone JR, Lindauer SE, et al. Use of functional analysis methodology in the evaluation of medication effects. J Autism Dev Disord 2003;33(3):271-9
   PubMed Web of Science ®Google Scholar
• Zarcone JR, Lindauer SE, Morse PS, et al. Effects of Risperidone on Destructive Behavior of Persons With Developmental Disabilities: III. Functional Analysis. Am J Ment Retard 2004;109(4):310-21
   PubMedGoogle Scholar